A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing

Breast Cancer Res Treat. 2018 Jul;170(2):425-430. doi: 10.1007/s10549-018-4742-x. Epub 2018 Mar 15.

Abstract

Background/purpose: Tumor heterogeneity is a now well-recognized phenomenon that can affect the classification, prognosis and treatment of human cancers. Heterogeneity is often described in primary breast cancers based upon histologic subtypes, hormone- and HER2-receptor status, and immunolabeling for various markers, which can be seen within a single tumor as mixed cellular populations, or as separate discrete foci.

Experimental design/methods: Here, we present a case report of a patient's primary breast cancer that had two separate but adjacent histologic components, one that was estrogen receptor (ER) positive, and the other ER negative. Each component was subjected to whole exome sequencing and compared for gene identity to determine clonal origin.

Results: Using prior bioinformatic tools, we demonstrated that both the ER positive and negative components shared many variants, including passenger and driver alterations. Copy number variations also supported the two components were derived from a single common clone.

Conclusions: These analyses strongly suggest that the two ER components of this patient's breast cancer were derived from the same clonal origin. Our results have implications for the evolution of breast cancers with mixed histologies, and how they might be best managed for optimal therapy.

Keywords: Breast cancer; Estrogen receptor; Whole exome sequencing.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Biomarkers, Tumor
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / genetics*
  • Clonal Evolution / genetics*
  • Computational Biology / methods
  • DNA Copy Number Variations
  • Estrogen Receptor alpha / genetics*
  • Exome Sequencing*
  • Female
  • Humans
  • Immunohistochemistry
  • Quantitative Trait Loci*

Substances

  • Biomarkers, Tumor
  • Estrogen Receptor alpha